Cargando…
Evaluating the natural growth rate of metastatic cancer to the brain
BACKGROUND: Brain metastases are becoming increasingly more prevalent as cancer patients survive longer with both improved local and systemic therapy. Little is known, however, of the natural growth rates of brain metastases. This investigation aims to ascertain this growth rate of these lesions bef...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533080/ https://www.ncbi.nlm.nih.gov/pubmed/33024592 http://dx.doi.org/10.25259/SNI_291_2020 |
_version_ | 1783590060208160768 |
---|---|
author | Kobets, Andrew J. Backus, Reid Fluss, Rose Lee, Alan Lasala, Patrick A. |
author_facet | Kobets, Andrew J. Backus, Reid Fluss, Rose Lee, Alan Lasala, Patrick A. |
author_sort | Kobets, Andrew J. |
collection | PubMed |
description | BACKGROUND: Brain metastases are becoming increasingly more prevalent as cancer patients survive longer with both improved local and systemic therapy. Little is known, however, of the natural growth rates of brain metastases. This investigation aims to ascertain this growth rate of these lesions before the initiation of any CNS- directed therapy. METHODS: A total of 700 patients were screened, identifying 18 cancer patients (13 breast and 5 lung) with 29 brain metastases that were serially imaged from 2011 to 2017 before treatment for their intracranial metastases. Growth rates were measured by contouring lesions serially across at least two MRI studies in iPlan software by independent raters. These values were then compared between primary (breast and lung) cancer cohorts. RESULTS: The mean age at diagnosis was 53 and 95% were female. The interval between primary cancer diagnosis and brain metastases was 4.6 years and 1.2 years in the breast and lung cancer groups, respectively. Of the breast and lung cancer patients, 23% and 40% were deceased, with respective 5.08 cm(3) and 2.44 cm(3) initial tumor volumes. The average growth rate of lung and breast tumors was 0.018 and 0.040 cm(3)/day, respectively, with deceased patients having larger and faster growing tumors. Breast and lung metastases grew 2.39% and 1.14% of their total volumes daily and doubling times were 86 and 139 days, respectively. CONCLUSION: This investigation provides a unique perspective into the biological growth of metastatic brain lesions. It is our hope that this study guides timing of treatment and informs both clinicians and patients of tumor growth kinetics before initiating treatment for intracranial metastases. |
format | Online Article Text |
id | pubmed-7533080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Scientific Scholar |
record_format | MEDLINE/PubMed |
spelling | pubmed-75330802020-10-05 Evaluating the natural growth rate of metastatic cancer to the brain Kobets, Andrew J. Backus, Reid Fluss, Rose Lee, Alan Lasala, Patrick A. Surg Neurol Int Original Article BACKGROUND: Brain metastases are becoming increasingly more prevalent as cancer patients survive longer with both improved local and systemic therapy. Little is known, however, of the natural growth rates of brain metastases. This investigation aims to ascertain this growth rate of these lesions before the initiation of any CNS- directed therapy. METHODS: A total of 700 patients were screened, identifying 18 cancer patients (13 breast and 5 lung) with 29 brain metastases that were serially imaged from 2011 to 2017 before treatment for their intracranial metastases. Growth rates were measured by contouring lesions serially across at least two MRI studies in iPlan software by independent raters. These values were then compared between primary (breast and lung) cancer cohorts. RESULTS: The mean age at diagnosis was 53 and 95% were female. The interval between primary cancer diagnosis and brain metastases was 4.6 years and 1.2 years in the breast and lung cancer groups, respectively. Of the breast and lung cancer patients, 23% and 40% were deceased, with respective 5.08 cm(3) and 2.44 cm(3) initial tumor volumes. The average growth rate of lung and breast tumors was 0.018 and 0.040 cm(3)/day, respectively, with deceased patients having larger and faster growing tumors. Breast and lung metastases grew 2.39% and 1.14% of their total volumes daily and doubling times were 86 and 139 days, respectively. CONCLUSION: This investigation provides a unique perspective into the biological growth of metastatic brain lesions. It is our hope that this study guides timing of treatment and informs both clinicians and patients of tumor growth kinetics before initiating treatment for intracranial metastases. Scientific Scholar 2020-08-21 /pmc/articles/PMC7533080/ /pubmed/33024592 http://dx.doi.org/10.25259/SNI_291_2020 Text en Copyright: © 2020 Surgical Neurology International http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Kobets, Andrew J. Backus, Reid Fluss, Rose Lee, Alan Lasala, Patrick A. Evaluating the natural growth rate of metastatic cancer to the brain |
title | Evaluating the natural growth rate of metastatic cancer to the brain |
title_full | Evaluating the natural growth rate of metastatic cancer to the brain |
title_fullStr | Evaluating the natural growth rate of metastatic cancer to the brain |
title_full_unstemmed | Evaluating the natural growth rate of metastatic cancer to the brain |
title_short | Evaluating the natural growth rate of metastatic cancer to the brain |
title_sort | evaluating the natural growth rate of metastatic cancer to the brain |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533080/ https://www.ncbi.nlm.nih.gov/pubmed/33024592 http://dx.doi.org/10.25259/SNI_291_2020 |
work_keys_str_mv | AT kobetsandrewj evaluatingthenaturalgrowthrateofmetastaticcancertothebrain AT backusreid evaluatingthenaturalgrowthrateofmetastaticcancertothebrain AT flussrose evaluatingthenaturalgrowthrateofmetastaticcancertothebrain AT leealan evaluatingthenaturalgrowthrateofmetastaticcancertothebrain AT lasalapatricka evaluatingthenaturalgrowthrateofmetastaticcancertothebrain |